1. Home
  2. MFIN vs SCTX Comparison

MFIN vs SCTX Comparison

Compare MFIN & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Medallion Financial Corp.

MFIN

Medallion Financial Corp.

N/A

Current Price

$9.47

Market Cap

273.7M

Sector

Finance

ML Signal

N/A

Logo Scribe Therapeutics Inc. Common Stock

SCTX

Scribe Therapeutics Inc. Common Stock

N/A

Current Price

$16.46

Market Cap

297.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MFIN
SCTX
Founded
1995
2017
Country
United States
United States
Employees
179
N/A
Industry
Finance: Consumer Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
273.7M
297.2M
IPO Year
N/A
2026

Fundamental Metrics

Financial Performance
Metric
MFIN
SCTX
Price
$9.47
$16.46
Analyst Decision
Hold
Strong Buy
Analyst Count
4
4
Target Price
$11.25
★ $57.00
AVG Volume (30 Days)
52.3K
★ 346.2K
Earning Date
10-29-2026
11-12-2026
Dividend Yield
★ 6.00%
N/A
EPS Growth
N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$12.27
N/A
P/E Ratio
$6.21
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.85
$13.50
52 Week High
$12.26
$39.60

Technical Indicators

Market Signals
Indicator
MFIN
SCTX
Relative Strength Index (RSI) 31.44 43.27
Support Level $9.30 $13.90
Resistance Level $10.10 $22.07
Average True Range (ATR) 0.46 1.58
MACD -0.11 0.33
Stochastic Oscillator 15.34 52.49

Price Performance

Historical Comparison
MFIN
SCTX

About MFIN Medallion Financial Corp.

Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.

About SCTX Scribe Therapeutics Inc. Common Stock

Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.

Share on Social Networks: